AdaptHealth names Suzanne Foster as CEO
AdaptHealth Corp. Appoints Suzanne Foster as CEO. Foster succeeds interim CEO and chairman of the board Richard Barasch. Foster previously served as the president of Beckman Coulter Life Sciences at Danaher (DHR) AHCO says Foster will take over as CEO on May 20.
Seeking Alpha · 22h ago
*AdaptHealth: Foster Was President of Danaher Unit Beckman Coulter
Dow Jones · 22h ago
*AdaptHealth: Foster to Replace Interim CEO Richard Barasch May 20; Barasch to Be Chmn Until June 30
Dow Jones · 22h ago
Noteworthy Wednesday Option Activity: TSLA, TRV, DHR
NASDAQ · 1d ago
Forecasting The Future: 7 Analyst Projections For Danaher
Danaher has been analyzed by 7 analysts in the last three months. The average price target for Danaher is $271.71. The company has a 12-month price target of $290.00. Danaher's revenue growth is lower than the average for the Health Care sector. The firm's net margin is above industry averages.
Benzinga · 1d ago
Danaher Raised to Buy From Hold by HSBC
Dow Jones · 1d ago
Danaher Price Target Raised to $280.00/Share From $250.00 by HSBC
Dow Jones · 1d ago
ProShares Ultra S&P500 Experiences Big Outflow
NASDAQ · 1d ago
HSBC Upgrades Danaher to Buy, Raises Price Target to $280
Benzinga · 1d ago
FHLC: Healthcare Dashboard For April
Healthcare sector is overvalued by 14% based on 11-year averages. The most overvalued subsector is healthcare equipment. Fidelity MSCI Health Care Index ETF is an alternative to XLV for long-term investors. This monthly article series reports aggregate industry metrics in healthcare.
Seeking Alpha · 1d ago
Fly High With Post-Breakup GE Stock
NASDAQ · 1d ago
BUZZ-Envista falls after new CEO appointment
Shares of dental products company Envista Holdings NVST.K fall 3.3% to $18.50 during aftermarket trade. Company announces appointment of Paul Keel as CEO effective May 1. Keel succeeds Amir Aghdaei, who served at 3M for 16 years.
Reuters · 2d ago
Analysts Expect 10% Upside For MGV
NASDAQ · 3d ago
Weekly Report: what happened at DHR last week (0408-0412)?
Weekly Report · 3d ago
Ensemble Capital Management Q1 2024 Letter
Ensemble Capital Management Q1 2024 Letter. The market staged a significant rally in the first quarter of 2024, jumping 10.56%. The market rally has been powered by the economic dynamics we described last quarter. The US economy has avoided a recession and inflation worries have faded.
Seeking Alpha · 5d ago
Reasons Why Danaher (DHR) Should be in Your Portfolio Now
NASDAQ · 6d ago
Here It Is! My 20-Stock 6-Figure Market-Beating Dividend Portfolio
Leo Nelissen's 20-stock dividend growth portfolio contains close to 95% of his net worth. He hasn't updated his portfolio in more than a year. In this article, he shares his view on inflation. He expects to outperform the market by an even wider margin in the years ahead.
Seeking Alpha · 6d ago
WRAPUP 3-China's March exports and imports shrink, miss forecasts by big margins
China's March exports and imports shrink, miss forecasts by big margins. March exports, imports fall more than expected in March. Exports from China slumped 7.5% year-on-year in March, the biggest fall since August last year. Imports for March also disappointed, declining 1.9% year on year. In first quarter, both exports and import both up 1.5%.
Reuters · 6d ago
Danaher Is Maintained at Equal-Weight by Barclays
Dow Jones · 04/10 19:44
Webull provides a variety of real-time DHR stock news. You can receive the latest news about Danaher Corporation through multiple platforms. This information may help you make smarter investment decisions.
About DHR
Danaher Corporation is a global life sciences and diagnostics innovator. The Company operates through three business segments: Biotechnology, Life Sciences and Diagnostics. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a broad range of equipment, consumables and services that are primarily used by customers to advance and accelerate the research, development, manufacture and delivery of biological medicines. The Life Sciences segment offers a range of instruments, consumables, services and software that are primarily used by customers to study genomics and the basic building blocks of life, including deoxyribonucleic acid (DNA)and ribonucleic acid (RNA), nucleic acid, proteins, metabolites and cells. The Diagnostics segment offers clinical instruments, consumables, software and services that hospitals, physicians’ offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions.